Brain serotonin deficiency and fluoxetine lead to sex-specific effects on binge-like food consumption in mice

Karth, Melinda D.; Baugher, Brittany J.; Pellechia, Sophia A; Huq, Shama N; Warner, Allison K; Karth, Michelle M.; Sachs, Benjamin D.

doi:10.1007/s00213-022-06181-x

Cited by 5 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described in Table 1, 16 studies [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] were identified that used compounds acting on the biogenic amine systems. Male Wistar rats were training to nose poke for binge food or standard chow pellets on fixed ratio and progressive ratio (PR) testing.…”

Section: Biogenic Amines and Related Compoundsmentioning

confidence: 99%

“…As described in Table 1, 16 studies [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] were identified that used compounds acting on the biogenic amine systems. • Binge intake was similar with or without intermittent calorie restriction (Restrict).…”

Section: Biogenic Amines and Related Compoundsmentioning

confidence: 99%

Section: Serotonergic-acting Compoundsmentioning

confidence: 99%

“…Four compounds (FLX, fenfluramine, lorcaserin, and WAY163909) were used to target the central serotonergic system [38,41,48,49,53]. A selective serotonin reuptake inhibitor (SSRI), FLX was administered a single peripheral dose (30 mg/kg) or chronic dose (150 mg/L in drinking water for 21 days) to assess binge eating in mice with a knock-in of tryptophan hydroxylase 2 (Tph2) [53]. Peripherally administered FLX at 3 mg/kg reduced binge eating in female rats with a history of caloric restriction [41], whereas FLX at 2 mg/kg reduced binge eating in female rats exposed to acute foot shock stress [38].…”

Section: Serotonergic-acting Compoundsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

et al. 2023

View full text Add to dashboard Cite

Recent advances in developing and screening candidate pharmacotherapies for psychiatric disorders have depended on rodent models. Eating disorders are a set of psychiatric disorders that have traditionally relied on behavioral therapies for effective long-term treatment. However, the clinical use of Lisdexamfatamine for binge eating disorder (BED) has furthered the notion of using pharmacotherapies for treating binge eating pathologies. While there are several binge eating rodent models, there is not a consensus on how to define pharmacological effectiveness within these models. Our purpose is to provide an overview of the potential pharmacotherapies or compounds tested in established rodent models of binge eating behavior. These finding will help provide guidance for determining pharmacological effectiveness for potential novel or repurposed pharmacotherapies.

show abstract

Section: Biogenic Amines and Related Compoundsmentioning

confidence: 99%

“…As described in Table 1, 16 studies [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] were identified that used compounds acting on the biogenic amine systems. • Binge intake was similar with or without intermittent calorie restriction (Restrict).…”

Section: Biogenic Amines and Related Compoundsmentioning

confidence: 99%

Section: Serotonergic-acting Compoundsmentioning

confidence: 99%

Section: Serotonergic-acting Compoundsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…While 5-HT in the brain only accounts for about 3–5% of the body’s serotonin, it plays a crucial role in regulating appetite [ 46 , 47 ]. Generally, an increase in 5-HT reduces food intake, while a reduction in 5-HT increases food intake [ 47 , 48 ]. In fact, after a meal, extracellular 5-HT levels increase in the medial hypothalamus of rats [ 49 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review

Conde

Fang

2023

Cell Biosci

View full text Add to dashboard Cite

The prevalence of obesity is rapidly increasing worldwide, while the development of effective obesity therapies lags behind. Although new therapeutic targets to alleviate obesity are identified every day, and drug efficacy is improving, adverse side effects and increased health risks remain serious issues facing the weight-loss industry. Serotonin, also known as 5-HT, has been extensively studied in relation to appetite reduction and weight loss. As a result, dozens of upstream and downstream neural targets of 5-HT have been identified, revealing a multitude of neural circuits involved in mediating the anorexigenic effect of 5-HT. Despite the rise and fall of several 5-HT therapeutics in recent decades, the future of 5-HT as a therapeutic target for weight-loss therapy looks promising. This review focuses on the history of serotonin, the state of current central serotonin research, previous serotonergic therapies, and the future of serotonin for treating individuals with obesity.

show abstract

Oligonol enhances brain cognitive function in high-fat diet-fed mice

Choi,

Ahn,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Brain serotonin deficiency and fluoxetine lead to sex-specific effects on binge-like food consumption in mice

Cited by 5 publications

References 55 publications

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review

Oligonol enhances brain cognitive function in high-fat diet-fed mice

Contact Info

Product

Resources

About